- Biotechnology company Cynata Therapeutics (CYP) has opened patient enrolment for its MEND COVID-19 trial
- The clinical-stage biotechnology company specialises in cell therapeutics and received ethics approval for it MEseNchyal COVID-19 trial in May
- The trial will be conducted at centres in NSW in collaboration with the Cerebral Palsy Alliance Research Institute and investigators from a COVID-19 stem cell treatment group
- The controlled clinical trial will investigate early efficacy of Cymerus MSCs in 24 adult patients admitted with COVID 19 and respiratory distress
- The trial’s primary goal is seeing an improvement in a patient’s Pa02/Fi02 ratio — a measurement of low oxygen levels in the bloodstream — by day seven of the study
- The safety and tolerability of the treatment will be assessed over 28 days and is considered another key goal
- Cynata Therapeutics closed 14.63 per cent in the green at 94 cents
Biotechnology company Cynata Therapeutics (CYP) has opened patient enrolment for its MEND COVID-19 trial.
The company specialises in cell therapeutics and announced it received ethics approval for the trial in May.
The MEseNchyal COVID-19 (MEND) trial will be conducted at centres in NSW in collaboration with the Cerebral Palsy Alliance Research Institute and investigators from the COVID-19 stem cell treatment group.
The trial will assess the early efficacy of Cymerus mesenchymal stem cells (MSCs) in 24 adults patients admitted to intensive care with COVID-19 while experiencing respiratory distress.
Cymerus is Cynata’s proprietary therapeutic stem cell platform technology and has demonstrated utility in preclinical models of asthma, heart attack and acute respiratory distress syndrome (ARDS), among others.
Half of the patients will receive a Cymerus MSC infusion along with the standard of care treatment, while the remaining 12 will form the control group and receive only the standard of care treatment.
The study will be an open-label trial, meaning information won’t be withheld from participants.
The trial’s primary goal is seeing an improvement in a patient’s Pa02/Fi02 ratio — a measure of hypoxemia, a low level of oxygen in the blood caused by less-than-optimal lung functioning — by day seven of the study.
The safety and tolerability of the treatment will be assessed over 28 days and is considered another key goal.
Cynata Therapeutics closed 14.63 per cent in the green at 94 cents.